RYTM Overview
Upcoming Projects (RYTM)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (RYTM)
-
A Look at the Recent FDA Approval of Rhythm Pharmaceuticals' IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
Tickers: RYTM, LLY, NVO
Executed On: Apr 01, 2026 at 03:00 PM EDT -
Discussing the topline results of Rhythm Pharma's setmelanotide for the treatment of hypothalmic obesity
Ticker: RYTM
Executed On: Apr 09, 2025 at 04:15 PM EDT -
Discussing setmelanotide as a potential therapy for hypothalmic obesity
Ticker: RYTM
Executed On: Jan 29, 2024 at 12:00 PM EST -
Discussing the potential of Rhythm Pharmaceuticals' Imcivree (Setmelanotide injection) in patients with hypothalamic obesity
Ticker: RYTM
Executed On: Jul 19, 2023 at 02:15 PM EDT -
A look at the FDA's approval for an obesity management drug for those with ultra-rare genetic diseases, this time for Bardet-Biedl syndrome
Ticker: RYTM
Executed On: Sep 09, 2022 at 11:00 AM EDT -
Discussing the potential of Rhythm Pharma's setmelanotide in treating Bardet-Biedl Syndrome
Ticker: RYTM
Executed On: Mar 09, 2022 at 02:00 PM EST
Expired Projects (RYTM)
-
Discussing Rhythm Pharmaceuticals’ IMCIVREE (setmelanotide) following Phase 2 Results in Hypothalamic Obesity
Ticker: RYTM
Execute By: Aug 31, 2022
Upcoming & Overdue Catalysts (RYTM)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (RYTM)
-
Rhythm Pharmaceuticals (RYTM) Announces Phase 2 Data of Setmelanotide in Additional MC4R Pathway Deficiency-related Obesities
Ticker: RYTM
Occurred on: Jan 26, 2021
Strategic Initiatives (RYTM)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
